Company Adimmune Corporation

Company Adimmune Corporation

4142

TW0004142005

Pharmaceuticals

Equities

4142

TW0004142005

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
27.8 ^TWD	+9.88%		+4.71%	-16.14%

Mar. 28	Adimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 05	An unknown buyer acquire 2.14% stake in Adimmune Corporation from BioEngine Technology Development Inc. for NTD300 million.	CI

ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.

Number of employees: 564

TWD in Million	2022	Weight	2023	Weight	Delta
Adimmune 97.6 %	2,064	91.6 %	1,742	97.6 %	-15.60%
Enimmune 2.4 %	188	8.4 %	43	2.4 %	-76.87%

TWD in Million	2022	Weight	2023	Weight	Delta
Taiwan 47.2 %	959	42.6 %	842	47.2 %	-12.16%
China 26.8 %	632	28.1 %	478	26.8 %	-24.45%
United States 18.3 %	346	15.4 %	327	18.3 %	-5.45%
Others 7.7 %	315	14.0 %	138	7.7 %	-56.08%

Managers	Title	Age	Since
Chung Cheng Liu CEO	Chief Executive Officer	-	19-06-19
Yin Teng Chang DFI	Director of Finance/CFO	-	20-12-31
Chi Hsien Chan CHM	Chairman	-	08-06-30
Zheng Dow Lee CTO	Chief Tech/Sci/R&D Officer	-	22-01-25
Suh Chin Wu CTO	Chief Tech/Sci/R&D Officer	-	21-08-31
Li Ya Tang ADM	Chief Administrative Officer	-	15-07-31
Chin Chuan Chang COO	Chief Operating Officer	-	04-10-31
Fei Pan IRC	Investor Relations Contact	-	12-02-29

Members of the board	Title	Age	Since
Jung Chin Lin BRD	Director/Board Member	70	19-06-19
Hsiao Po Hsu BRD	Director/Board Member	-	11-08-14
Chi Hsien Chan CHM	Chairman	-	08-06-30
Wei-Kuang Chi BRD	Director/Board Member	-	01-06-07
Chien Fu Chen BRD	Director/Board Member	-	17-06-28
Mei Hsiang Ho BRD	Director/Board Member	-	17-06-28
Ching Che Lin BRD	Director/Board Member	-	17-06-28
Mei Hsing Tseng BRD	Director/Board Member	-	17-06-28
Chi Heng Lin BRD	Director/Board Member	-	08-10-29
Yung Sheng Hsu BRD	Director/Board Member	-	20-06-21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	429,508,000	295,214,750 ( 68.73 %)	8,000,000 ( 1.863 %)	68.73 %

Name	Equities	%	Valuation
DFA Australia Ltd. 0.007754 %	33,304	0.007754 %	27 837 NT$
Dimensional Fund Advisors Ltd. 0.003036 %	13,039	0.003036 %	10 899 NT$

Adimmune Corp.

3 Section 1, Tanxing Road Tanzi District

427 23, Taichung

+886 4 2538 1220

http://www.adimmune.com.tw

Company calendar

	1st Jan change	Capi.
ADIMMUNE CORPORATION	-16.14%	361M
CSL LIMITED	-5.32%	84.57B
SAMSUNG BIOLOGICS CO.,LTD.	+2.11%	39.93B
BIOGEN INC.	-26.14%	27.93B
UCB	+52.09%	24.21B
BIOMARIN PHARMACEUTICAL INC.	-5.51%	17.17B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-31.09%	13.93B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.58%	12.3B
INCYTE CORPORATION	-16.36%	11.84B
SWEDISH ORPHAN BIOVITRUM AB	-2.92%	7.91B

Biopharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals